1 Min Read
March 15 (Reuters) - Merck & Co Inc : * Says FDA will take extra 3 months to review sugammadex anesthesia-reversal
agent * Says now expects FDA review of marketing application to be completed in
second half 2013
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.